23. International CML Workshop

On June 26-27, the 23. International CML Workshop will be held in Mannheim, Germany. Topics are current clinical trials and pathogenesis and management of CML in blast crisis. The workshop is followed by a EUTOS meeting focussing on the outcome and next steps of the subprojects Molecular monitoring, CML Registry and Path to cure. ▶ detailed information on the workshop

Schedule of the WP meetings at the 19th Congress of EHA

From June 12 to 15 the 19th Congress of the European Hematology Association takes place in Milan, Italy. On June 12 the ELN workpackages will meet at MiCo, Viale Eginardo (Gate 2). ▶ schedule of WP meetings

Publications from the Network (selected)

Acute lymphoblastic leukemia

▶ Soverini S et al. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement. Cancer. 2014 Apr 1;120(7):1002-9.

Acute myeloid leukemia

▶ Duployez N et al. Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA. Am J Hematol. 2014 May;89(6):610-5.


**Chronic myeloid leukemia**


**Chronic lymphocytic leukemia**


**Myelodysplastic syndromes**


**Myeloproliferative neoplasms**

- Campanelli R et al. CD14(bright)CD16(low) intermediate monocytes expressing Tie2 are increased in the peripheral blood of patients with primary myelofibrosis. Exp Hematol. 2014 Apr;42(4):244-6.

**Stem cell transplantation**


**Miscellaneous**


**New trials in the ELTR**

**TOWER** A Phase 3, Randomized, Open Label Study Investigating the Efficacy of the BiTE Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study)

**ALCANTARA** A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE Antibody Blinatumomab in Adult Subjects With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia (Alcantara Study)